ruihua xu, MD
Sun Yat-Sen University Cancer Center · Sun Yat-sen University Cancer Center (SYSUCC) · Sun Yat-sen University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name ruihua xu, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 13:21 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT07915921 · A Phase Ib/II Study of GFH276 in Combination With Chemotherapy (± Bevacizumab) or Cetuximab in Patients With RAS-mutant Metastatic Colorectal CancerGenfleet Therapeutics (Shanghai) Inc. · not yet recruiting · CRC · principal investigator
- Ph1NCT07809607 · A Study to Evaluate YF087 in Subjects With MSI-H or dMMR Advanced Solid TumorsInventisBio Co., Ltd · not yet recruiting · Advanced Solid Tumor Cancer · principal investigator
- Ph2NCT07021950 · AK112 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI as Second-line Treatment of MSS/pMMR Metastatic Colorectal CancerSun Yat-sen University · not yet recruiting · Colorectal Cancer, Ivonescimab · principal investigator
- Ph2NCT05962502 · Cetuximab Plus Irinotecan in Patients With NeoRAS Wild-type Metastatic Colorectal Cancer In Third-line TherapySun Yat-sen University · recruiting · Metastatic Colorectal Cancer · principal investigator
- Ph3NCT05918094 · Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction AdenocarcinomaSun Yat-sen University · recruiting · Gastric Cancer · principal investigator
- Ph1NCT05781386 · A Phase I Trial of SIM1811-03 in Subjects With Advanced TumorsJiangsu Simcere Biologics Co., Ltd · unknown · Advanced Solid Tumor, Cutaneous T Cell Lymphoma · principal investigator
- Ph3NCT05768503 · Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRCSun Yat-sen University · recruiting · Metastatic Microsatellite-stable Colorectal Cancer · principal investigator
- N/ANCT05557955 · Identification of Breath Biomarkers in Esophageal CancerMian XI · completed · Esophageal Squamous Cell Carcinoma · study director
- Ph2NCT05520619 · Combination of Tislelizumab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-002)Sun Yat-sen University · active not recruiting · Esophageal Squamous Cell Carcinoma, Locally Advanced Esophageal Squamous Cell Carcinoma · principal investigator
- Ph2NCT05163483 · Tucidinostat Plus PD-1 Inhibitor and Bevacizumab for Advanced Esophagus Cancer, AEG, Gastric CancerRuihua Xu · unknown · Esophageal Squamous Cell Cancer, Adenocarcinoma of Esophagogastric Junction, Gastric Adenocarcinoma · principal investigator
- Ph1NCT04991129 · The Safety and Efficacy of Multiple-dose of WJ01024 in Subject With Advanced CancerSuzhou Junjing BioSciences Co., Ltd. · terminated · Advanced Hematologic Malignancies, Advanced Solid Tumors · principal investigator
- Ph2NCT04724239 · Sintilimab and Chidamide in Combination With or Without IBI305 in Advanced or Metastatic pMMR/MSS Colorectal CarcinomaSun Yat-sen University · unknown · Advanced Microsatellite Stable Colorectal Cancer, Metastatic Microsatellite-stable Colorectal Cancer · principal investigator
- Ph2NCT04547101 · A Study of AK104 in Subjects With Locally Advanced Unresectable or Metastatic MSI-H/dMMR Solid TumorsAkeso · terminated · MSI-H/dMMR Solid Tumor · principal investigator
- Ph3NCT04262635 · Cetuximab Plus Capecitabine as Maintenance Treatment in RAS and BRAF wt Metastatic Colorectal CancerSun Yat-sen University · unknown · Colorectal Cancer · study chair
- N/ANCT04228614 · Evaluation of Somatic Mutation Spectrum as Biomarker for Survival Outcome in Chinese CRCSun Yat-sen University · unknown · Colorectal Cancer · study director
- Ph2NCT04220307 · A Study of a PD-1/CTLA-4 Bispecific Antibody AK104 in Patients With Metastatic Nasopharyngeal CarcinomaAkeso · completed · Nasopharyngeal Carcinoma · study chair
- Ph2NCT03906565 · Clinical Study of Utidelone Injection in Patients With Advanced or Metastatic Colorectal CancerBeijing Biostar Pharmaceuticals Co., Ltd. · suspended · Advanced or Metastatic CRC · principal investigator
- N/ANCT03312374 · ctDNA as a Prognostic Marker for Postoperative Relapse in Early and Intermediate Stage Colorectal CancerSun Yat-sen University · unknown · Colorectal Cancer · study chair
- Ph3NCT03223376 · A Phase III Study of Fruquintinib in Combination With Paclitaxel in Second Line Gastric Cancer(FRUTIGA)Hutchison Medipharma Limited · completed · Advanced Gastric Cancer · principal investigator
- Ph1NCT03182673 · The Study of SHR7390 in Combination With SHR-1210 and SHR3162 in Patients With Advanced Solid TumorsJiangsu HengRui Medicine Co., Ltd. · terminated · Solid Tumor · principal investigator
- Ph1NCT02968485 · Phase I Study of SHR7390 in Patients With Advanced Solid TumorsJiangsu HengRui Medicine Co., Ltd. · unknown · Solid Tumor · principal investigator
- Ph1/Ph2NCT02915432 · The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCCShanghai Junshi Bioscience Co., Ltd. · unknown · Gastric Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Nasopharyngeal Carcinoma · principal investigator
- Ph1NCT02857166 · Study of JS001 in Participants With Advanced Solid TumorsShanghai Junshi Bioscience Co., Ltd. · completed · Solid Tumors · principal investigator
- Ph3NCT01996306 · A Phase III Study of 2nd-line XELIRI ± Bevacizumab vs. FOLFIRI ± Bevacizumab in mCRCEpidemiological and Clinical Research Information Network · completed · Colorectal Neoplasms, Neoplasm Metastasis, Intestinal Neoplasms · principal investigator
- N/ANCT01549067 · The Real Clinical Background of Advanced Colorectal Cancer Treatment Situation SurveyChinese Medical Doctor Association · unknown · Advanced Malignant Neoplasm, Colorectal Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 13:21 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in colorectal cancer.